The patent application US20240350420A1 focuses on pharmaceutical formulations and methods for treating conditions such as hyperhidrosis, which involves excessive sweating. The document details the development of modified-release compositions, specifically utilizing Pilocarpine HCl, a muscarinic agonist. These formulations aim to optimize drug delivery by employing various release mechanisms, including immediate, delayed, or sustained release. The innovations include encapsulation techniques using polymer coatings to control dissolution rates under different conditions, ensuring stable and effective drug delivery over time.
Additionally, the application highlights formulations combining Pilocarpine with other agents like Oxybutynin to enhance therapeutic efficacy. The study of dissolution profiles under varying environmental conditions further underscores the emphasis on stability and performance consistency. This approach is designed to improve patient outcomes by tailoring release profiles to meet specific medical needs while minimizing side effects through controlled drug exposure.
Why CELLETS® are important in these methods for treating hyperhidrosis
CELLETS® are microcrystalline cellulose spheres, serving as an essential component in drug delivery systems designed for controlled and extended release of active pharmaceutical ingredients (API). These spheres act as inert core substrates, providing a uniform and stable base for layering the active compounds and functional polymers. Their consistent size and smooth surface allow precise and even distribution of coatings, which is critical for achieving predictable drug release kinetics.
Cellets are the crucial base for formulations relying on pellet technologies. These powerful formulations for oral drug uptake allow improving the pharmacokinetic profile of APIs, especially highly lipophilic drugs, by controlling their release rate. By coating excipients and API, multi-layer systems created on these cores allow gradual drug dissolution, reducing fluctuations in drug plasma levels and minimizing side effects. For example, in this patent of a Pilocarpine HCl formulation, coating CELLETS® with siutable excipients enable extended drug release, maintaining therapeutic concentrations for longer durations and improving patient compliance by reducing dosing frequency.
Their flexibility in application allows them to be used across various dosage forms, such as capsules or compressed tablets and even gel-like dosage forms. Additionally, the uniformity of these MCC starter beads ensures that each pellet provides a controlled dose of the active ingredient, making them integral to achieving consistent therapeutic outcomes in complex drug delivery systems.
The function of Pilocarpine HCl
Pilocarpine HCl is a cholinergic agonist that stimulates muscarinic receptors to increase secretion production and smooth muscle contraction. It is primarily used in ophthalmology to treat glaucoma by reducing intraocular pressure through enhanced aqueous humor outflow. Additionally, it is used in managing xerostomia (dry mouth) caused by conditions like Sjögren’s syndrome or following radiation therapy for head and neck cancers. Its parasympathomimetic action helps stimulate saliva production and improve symptoms.
Document information
Document Type and Number: (“Pharmaceutical compositions and methods for treating hyperhidrosis”).
Inventors:
Disclaimer
This text was partly generated by chatGPT engine version GPT‑4o, on Nov 21, 2024. Image was generated with Adobe Firefly.
adobe firefly 
adobe firefly 
adobe firefly 
adobe firefly 
